Hypoxia‐mediated attenuation of EGLN2 inhibition of the NF‐κB signaling pathway leads to the formation of a loop between HIF‐1α and MUC1‐C promoting chemoresistance in bladder cancer

Abstract

AbstractThe expression pattern of MUC1‐C in tumors is closely linked to tumor progression; however, its specific mechanism remains unclear. The expression of MUC1‐C in cancer and adjacent normal tissues was detected using immunohistochemistry and Western blot. The IC50 of cells to gemcitabine was determined using the CCK8 assay. The effects of hypoxia and MUC1‐C on the behavioral and metabolic characteristics of bladder cancer cells were investigated. Gene expression was assessed through Western blot and polymerase chain reaction. The relationship between the genes was analyzed by co‐immunoprecipitation, immunofluorescence and Western blot. Finally, the role of the EGLN2 and NF‐κB signaling pathways in the interaction between MUC1‐C and hypoxia‐inducible factor‐1α (HIF‐1α) was investigated. MUC1‐C expression is significantly higher in bladder cancer tissues than in adjacent normal tissues, particularly in large‐volume tumors, and is closely correlated with clinical features such as tumor grade. Tumor volume‐mediated hypoxia resulted in increased expression of MUC1‐C and HIF‐1α in bladder cancer cells. Under stimulation of hypoxia, the inhibitory effect of EGLN2 on the NF‐κB signaling pathway was weakened, allowing NF‐κB to promote the positive feedback formation of MUC1‐C and HIF‐1α. Simultaneously, EGLN2‐mediated degradation of HIF‐1α was reduced. This ultimately led to elevated HIF‐1α‐mediated downstream gene expression, promoting increased glucose uptake and glycolysis, and ultimately resulting in heightened chemotherapy resistance and malignancy.